All In Biotech

Drug Trial Radar · NCT05162586

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging, Parallel and Adaptive Study to Evaluate the Efficacy and Safety of Enpatoran in SLE and in CLE (SCLE and/or DLE) Participants Receiving Standard of Care (WILLOW)

Last checked: Nov 19, 2026Latest source record: Dec 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 456 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

456

Actual

Start

Mar 31, 2022

Primary completion

Nov 20, 2024

Study completion Nov 20, 2024

Sponsor

Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
Dec 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Proof of Concept (PoC) and Dose-finding (DF) basket study is to evaluate the efficacy and safety of orally administered Enpatoran over 24 weeks in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE; subacute cutaneous lupus erythematosus \[SCLE\] and/or discoid lupus erythematosus \[DLE\]) participants in a randomized, double-blind, placebo-controlled, parallel, adaptive and dose-ranging setting. Study Duration: 33 weeks Visit Frequency: every 2 or 4 weeks Enpatoran is not available through an expanded access program.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • Enpatoran low doseDrug

    Participants will receive film-coated tablets of Enpatoran at a low dose orally, twice daily (BID) up to 24 weeks.

  • Enpatoran medium doseDrug

    Participants will receive film-coated tablets of Enpatoran at a medium dose, orally, BID up to 24 weeks.

  • Enpatoran high doseDrug

    Participants will receive film-coated tablets of Enpatoran at a high dose, orally, BID up to 24 weeks.

  • PlaceboDrug

    Participants will receive placebo matched to Enpatoran up to 24 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort A: Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index-A (CLASI-A) Total Score at Week 16Time frame: Baseline, week 16
  2. Cohort B: Number of Participants With British Isles Lupus Assessment Group (BILAG)-Based Composite Lupus Assessment (BICLA) Response at Week 24Time frame: At Week 24

Locations

153 sites in 22 countries. Site status is shown where the registry gives one.

  • The Lundquist Institute at Harbor-UCLA Medical Center

    Torrance, California

  • Bay Area Arthritis and Osteoporosis

    Brandon, Florida

  • Advance Medical Research Center

    Miami, Florida

  • New Horizon Research Center, Inc

    Miami, Florida

  • Charisma Medical and Research Center

    Miami Lakes, Florida

  • HMD Research, LLC

    Orlando, Florida

  • D&H Tamarac Research Center, LLC

    Tamarac, Florida

  • RNA America Health Sciences

    Sugar Hill, Georgia

  • Dawes Fretzin Dermatology Group, LLC

    Indianapolis, Indiana

  • AA MRC LLC Ahmed Arif Medical Research Center

    Grand Blanc, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Across the Life Span

    Smithfield, North Carolina

  • Ohio State University - CTMO Parent

    Columbus, Ohio

  • Ramesh C Gupta, MD - Memphis, TN

    Memphis, Tennessee

  • CINME - Centro De Investigaciones Metabolicas

    Buenos Aires, Argentina

  • Buenos Aires Skin

    Ciudad Autonoma Buenos Aires, Argentina

  • Centro Dermatologico Schejtman

    Ciudad Autonoma Buenos Aires, Argentina

  • Hospital Militar Central Dr. Cosme Argerich

    Ciudad Autonoma Buenos Aires, Argentina

  • Centro de Investigaciones Medicas Mar del Plata - CIM

    Mar del Plata, Argentina

  • Instituto de Reumatologia

    Mendoza, Argentina

  • Instituto Medico de la Fundacion Estudios Clinicos

    Rosario, Argentina

  • Instituto Medico de alta Complejidad San Isidro S.A (IMAC)

    San Fernando, Argentina

  • CER San Juan Centro Polivalente de Asistencia e Inv. Clinica

    San Juan, Argentina

  • PSORIAHUE-Medicina Interdisciplinar

    San Miguel, Argentina

  • Centro de Investigaciones Medicas Tucuman

    San Miguel de Tucumán, Argentina

  • Investigaciones Clinicas Tucuman

    San Miguel de Tucumán, Argentina

  • Monash Medical Centre Clayton

    Clayton, Australia

  • Westmead Hospital - SUPERSEDED

    Westmead, Australia

  • Veracity Clinical Research

    Woolloongabba, Australia

  • Santa Casa de Misericórdia de Belo Horizonte

    Belo Horizonte, Brazil

  • Oncovida - Centro de Onco-Hematologia de Mato Grosso

    Cuiabá, Brazil

  • CETI - Centro de Estudos em Terapias Inovadoras Ltda.

    Curitiba, Brazil

  • HUWC - UFC - Hospital Universitário Walter Cantídio - Universidade Federal do Ceará

    Fortaleza, Brazil

  • CMiP - Centro Mineiro de Pesquisa

    Juiz de Fora, Brazil

  • Hospital Bruno Born

    Lajeado, Brazil

  • Hospital Moinhos de Vento

    Porto Alegre, Brazil

  • Clínica SER da Bahia

    Salvador, Brazil

  • Fundação Faculdade Regional de Medicina de São José do Rio Preto - CIP - Centro Integrado de Pesquisa

    São José do Rio Preto, Brazil

  • CEPIC - Centro Paulista de Investigação Clínica e Serviços Médicos

    São Paulo, Brazil

  • CPCLIN - Centro de Pesquisas Clínicas Ltda.

    São Paulo, Brazil

Showing 40 of 153 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.